Exploring new ways to use antibodies as treatments for various diseases
Official title: Antibodies as Drugs: Innovative Formats, Design and Engineering
Funded at Keystone Symposia · NIH-11071876 · Data updated 2026-11-12
This study is all about a conference where experts will share new ideas on how to make antibody treatments better for diseases like cancer and autoimmune disorders, and they'll also talk about how technology can help improve these therapies, which could lead to better options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Keystone Symposia NIH-funded |
| Lab location | 1 site (Silverthorne, United States) |
| Project start | November 18, 2024 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $4,200 |
| NIH project number | 1R13AI188933-01 |
| Project ID | NIH-11071876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals affected by cancer, autoimmune diseases, or infectious diseases who are interested in the latest therapeutic advancements.
✕Less likely to help
Patients with conditions not related to antibody therapies or those who do not have access to the conference may not benefit from this research.
What this research studies
This research involves a conference focused on innovative designs and engineering of antibodies as therapeutic agents. It will bring together experts to discuss new formats and delivery methods that could enhance the effectiveness of antibody treatments for conditions like cancer, autoimmune diseases, and infections. The conference will also explore the role of artificial intelligence in advancing these therapies, aiming to foster collaboration and share insights among researchers. Patients may benefit from the latest findings and advancements in antibody therapies presented at this event.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibody treatments for a variety of diseases.
How similar studies have gone: Previous conferences and research in antibody therapies have shown promising advancements, indicating a strong potential for success in this area.
Where this research is happening
-
Keystone Symposia
Silverthorne, United States Active
Researchers
- Principal investigator: Sheppard, Terry L. — Keystone Symposia
- Study coordinator: Sheppard, Terry L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.